Moelis: Real Fees, a Clean Balance Sheet, and the Stubborn Cost of Capital

Moelis reported its best quarter in company history — record second-quarter revenue of $409.4 million, up 12% from a year ago — and the stock fell anyway. Over the past three weeks, MC has lost roughly 9%, and it still sits about $14.20 below its 52-week high of $78.22. The headline and the price are telling two different stories, and the gap between them is worth more than either one.

The useful question isn't whether Moelis had a great quarter — it clearly did. It's why the market won't reward one. The answer is narrower than the debate usually makes it, and it comes down to a single variable that keeps surfacing on the company's own earnings calls: the cost of capital.

What the record quarter actually shows

Let me be precise about what "record" means here, because it's better than "record revenue" alone. Moelis grew to $409.4 million of Q2 revenue — and $729.2 million for the first half, up 9% — mostly without doing more deals. Management was explicit that the growth came from higher average fees per completed transaction: fatter fees on more complex mandates, not a bigger deal count.

That distinction matters a lot for an advisory bank, because your entire cost base is people. When fees per deal rise, the margin follows. The adjusted pre-tax margin expanded to 18.6% in Q2 from 17.6% a year earlier, and the compensation ratio — the single biggest line on the income statement — actually improved to 65.8% from 69%. The company also entered the second half with a record announced pipeline, more than 80% larger than a year ago.

So the "bucking trends" is real and it's quality-driven. Moelis is winning share in exactly the complicated work the big banks deprioritize — the $8.5 billion Taylor Morrison sale, the $4.1 billion Magnolia Oil & Gas deal, a $3.8 billion Iqvia sale.

One number is doing all the work on the sell side

If the quarter is a record and the pipeline is the biggest in the company's history, why is the stock down? Because the market isn't pricing the last quarter. It's pricing the pace — and the pace runs on one input.

The cost of capital is the return a private-equity sponsor needs to justify funding and closing a buyout. That return has not come back down. The bears argue that this stubborn, elevated cost of capital is precisely what's keeping sponsors from making a full return to dealmaking, and it's the reason the bigger, more profitable leveraged-buyout deals that feed an advisory bank like Moelis stay slower than the recovery headline implies.

Moelis's own management put it plainly. Sponsor M&A has been modest year to date, especially in the mid-market, and some sponsor-owned companies — the highly levered ones, and those hit by disruption — are simply hard to exit at the returns their owners want.

That's also why the "soft spot" in the quarter was capital structure advisory, where growth lagged and liability-management work — helping heavily indebted companies rework their debt — dominated the mix. In plain terms: when the cost of capital is high, a lot of the fee-generating work is distressed and defensive rather than the organic, value-creating M&A that peaks a bank's margins. And Moelis itself warns that its revenue is milestone-driven and lumpy, which means a record quarter doesn't promise the next one.

The same number, from the other side

Here's the part the headline misses, and the part I find most useful. The very thing the bears are worried about — a high, stubborn cost of capital — is also creating the work Moelis is deliberately growing.

When the cost of capital stays elevated, companies can't easily refinance, can't exit at good prices, and have to restructure. That isn't a temporary glitch; it's a recurring stream of assignments for a firm that has been quietly building it out. In the first half, Moelis posted record revenue in capital markets and in private capital advisory — the areas where it added senior bankers into private credit secondaries, securitization, debt capital markets, and energy. First-half revenue was roughly two-thirds M&A and one-third non-M&A, and management is investing to make that non-M&A share bigger and more predictable.

The company is, in effect, trading some of the peak, lumpy LBO-fee potential for a steadier, less-cyclical fee base — which is exactly what you want when your revenue depends on deal closings.

And the survival test, which is the one I run first on any cash-flow business, is a non-issue here. Moelis ended the quarter with no funded debt and $481.1 million in cash and short-term investments, and it generated roughly $433 million of free cash flow over the trailing twelve months. That cash is what pays for everything, and it's why the distribution looks safe even though it looks aggressive. The company returned about $246 million to shareholders in the first half — roughly $141 million in buybacks and $105 million in dividends — and just declared another $0.65 quarterly dividend, a roughly 4% yield, with a payout ratio of about 92% of earnings per share. On an income basis that ratio would frighten me; on a cash basis it's comfortable, because the payout is funded by free cash flow, not by borrowed money.

The margin of safety is the actual question

Now the valuation, where I get less confident. At about $64, Moelis trades near 22 times trailing earnings and yields around 4%. Its closest large-independent comparable, Houlihan Lokey, runs at a similar multiple — about 23.5 times — so Moelis is not sitting at a 30% discount that would make a re-rating case easy. It is also trading near the level most analysts already put on fair value.

That means my read is not "deeply undervalued, buy the dip." It's narrower, and I think more honest. The cash flow is real and durable, the balance sheet is clean, and the downside is cushioned by a 4% yield and a debt-free balance sheet — so this is not a value trap. But there is no fat margin of safety at this price, because the market is not wrong about the thing that matters: the cost of capital is still high, and until it comes down, the pace of the big sponsor deals stays capped.

This is a cyclical-pace question, not a survival question. The single variable that changes my mind in either direction is the cost of capital itself. If sponsor buyout returns normalize — the full-fledged return of dealmaking the bears say is being held back — Moelis re-rates, and the record pipeline turns into record revenue at scale. If the cost of capital stays stubborn, the diversified, recurring fees carry the business just fine, but the upside stays capped and you're being paid mainly by the dividend for waiting. Either way, the honest answer to why a record quarter isn't moving the stock is the same one number, and it's one the company can't control: what it costs its clients to raise and deploy capital.